Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of tolerability safety, and pharmacokinetics of hOKT3g1 (Ala-Ala) [teplizumab]

Trial Profile

Evaluation of tolerability safety, and pharmacokinetics of hOKT3g1 (Ala-Ala) [teplizumab]

Phase of Trial: Phase I

Latest Information Update: 19 Jan 2010

At a glance

  • Drugs Teplizumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jan 2010 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
    • 06 Dec 2007 Status changed from in progress to completed.
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top